Additional in vivo data presented suggest that exogenous low dose Interleukin-2 (IL-2) support can significantly enhance the expansion and persistence of CAR-T cells to boost CAR-T efficacy without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback